A Treatment Option for Acute Steroid-Refractory Graft-Versus-Host Disease (GVHD): What to Expect

Learn what to expect when taking Jakafi® (ruxolitinib) to help treat acute graft-versus-host disease (GVHD) when steroids did not work well enough. Oncology Clinical Nurse Educator Emily Knight reviews topics such as how to take Jakafi, when the medication should be taken, and what tests are recommended along the way. Additionally, Emily reviews safety information and how to enroll in IncyteCARES, the patient support program for people taking Jakafi.

Jakafi is the first and only prescription medicine approved by the FDA to treat adults and children 12 years of age and older with acute graft-versus-host disease who have taken corticosteroids and they did not work well enough.

This video is intended for informational use only and is not designed to replace the medical advice of your Healthcare Professional. Please see your Healthcare Professional if you have further questions. Please watch and carefully review the Important Safety Information presented in this video and see the accompanying Full Prescribing Information including Patient Information.

For more information about Jakafi, visit https://www.jakafi.com/register.aspx.
Selected Safety Information

Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for acute GVHD include: low platelet counts, low red or white blood cell counts, infections, and swelling. Call your doctor for medical advice about side effects.

To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/.

Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte.
© 2020, Incyte Corporation. MAT-JAK-03729 01/22